Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs

The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments

Briefs: CuraTeQ Biologics, Sigachi Industries and Natural Capsules

CuraTeQ Biologics and BioFactura USA to terminate agreement mutually

Sigachi Industries posts Q2 FY2026 consolidated profit at Rs. 10.68 Cr

Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025

Sigachi Industries reports Q1 FY26 consolidated loss at Rs. 100.35 Cr

Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025

Sigachi Industries begins disbursing Interim ex-gratia to families of deceased

Sigachi Industries appoints Lijo Stephen Chacko as Deputy Group CEO

Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries

Sigachi Industries gets ToR approval for API and specialty chemicals manufacturing facility in Andhra Pradesh

The project will be instrumental in enhancing the company's API manufacturing capacity and global reach

Sigachi Industries FY25 revenue surges 25%, EBITDA 46%

Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients

Sigachi Industries receives CEP for Metformin Hydrochloride from EDQM

The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets

Sigachi Industries signs MoU with Respilon Group

This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.